Chordia Therapeutics Inc. (190A) AI Stock Analysis

• Market Cap: ¥8.75B
• Dividend Yield: N/A
• Average Volume (3M): 565.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -4.24
• Shares Outstanding: 71,167,900
• 10 Day Avg. Volume: 542,310
• 30 Day Avg. Volume: 565,443
• PEG Ratio: 0.42
• Price to Book (P/B): 5.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: ¥119.00 ▲(10.19% Upside)

The score is primarily driven by weak financial performance (zero revenue in 2024–2025, large losses, and heavy cash burn despite no debt). Technical indicators are mixed but not supportive of a strong trend, and valuation support is limited due to negative earnings and no dividend yield.

Positive Factors

Debt-free balance sheet

Having no reported debt materially reduces financial risk and interest obligation for a small biotech. This structural flexibility supports continued R&D spending or strategic deals without immediate debt servicing constraints, improving options for financing programs over months.

Proven ability to generate revenue in 2023

The company demonstrated it can convert R&D into commercial revenue and profit in 2023. This indicates operational and commercial capability exists, providing a durable baseline that, if programmes progress, increases the probability of future revenue recovery versus peers that never commercialized.

Focused small-molecule oncology pipeline

A concentrated focus on small-molecule oncology targeting high unmet needs is a durable strategic strength: specialization can yield deeper domain expertise, clearer go-to-market paths, and attractive partnering opportunities, supporting long-term value creation if clinical progress continues.

Negative Factors

Zero revenue and large net losses in 2024–2025

Reverting to a zero‑revenue profile with substantial losses is a material structural weakness. It erodes internal funding capacity, increases reliance on external capital, and reduces visibility into sustainable operations, raising the risk that R&D programmes cannot be advanced without dilution or deals.

Sustained negative operating cash flow

Large negative operating cash flows over consecutive years indicate real cash burn from operations rather than accounting losses. This persistent outflow materially shortens runway, making external financing or partnerships likely and creating execution risk for multi‑period clinical programs.

Material equity erosion and deeply negative ROE

A halving of equity and very negative ROE reflect sustained value destruction and a weakening capital base. This reduces the firm’s ability to absorb setbacks, limits financial flexibility, and raises the likelihood of dilutive financing or constrained strategic choices over the medium term.

Chordia Therapeutics Inc. Business Overview & Revenue Model

Company Description

Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.

How the Company Makes Money

Chordia Therapeutics Inc. primarily generates revenue through the development and commercialization of its proprietary drug candidates. The company earns income from licensing agreements, milestone payments, and royalties from partnerships with larger pharmaceutical companies. These collaborations often involve co-development or marketing arrangements that help Chordia Therapeutics bring its therapies to market. Additionally, the company may receive funding through grants, research collaborations, and potential government or non-governmental support aimed at fostering innovation in cancer treatment.

Chordia Therapeutics Inc. Financial Statement Overview

Summary

Financial results are weak and highly volatile: the company swung from profitable operations and positive cash generation in 2023 to zero revenue with large net losses in 2024–2025, alongside heavy operating cash outflows. The main offset is a debt-free balance sheet, but equity has materially eroded from sustained losses.

Income Statement

Operating performance has deteriorated sharply: after a profitable year in 2023 (revenue 2.5B and positive EBIT/Net Income), the company returned to a zero-revenue profile in 2024–2025 with very large losses (2025 Net Income about -1.79B). Margins are effectively nonexistent in the latest periods due to no revenue, and profitability is highly volatile—suggesting an early-stage/biotech-style earnings profile with limited near-term visibility. A key strength is that the business has demonstrated it can generate revenue and profits (2023), but the recent step-down back to heavy losses dominates the outlook.

Balance Sheet

The balance sheet shows no reported debt across periods, which reduces financial risk and improves flexibility. However, equity has declined materially (from ~4.50B in 2023 to ~2.44B in 2025), reflecting sustained losses and weakening the capital base; returns on equity are strongly negative in the most recent years (2025 ROE roughly -73%). Assets have also trended down versus the 2023–2024 levels, indicating cash burn and/or asset consumption. Overall: low leverage is a clear positive, but shrinking equity is a meaningful concern.

Cash Flow

Cash generation is weak and volatile: 2023 produced positive operating cash flow (~544M) and free cash flow (~543M), but 2024 and 2025 reverted to sizable cash outflows (operating cash flow about -1.94B in 2024 and -1.84B in 2025). Free cash flow is negative and worsening versus the prior profitable year, consistent with heavy investment/spend without offsetting revenue. A relative positive is that cash flow tracks net income closely (free cash flow to net income ~1x), but that mainly reflects that losses are translating into real cash burn.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	2.50B	0.00	800.00M
Gross Profit	-2.89M	-1.43B	-4.09M	503.18M	-3.15M	800.00M
EBITDA	-2.02B	-1.79B	-1.82B	218.10M	-1.77B	-687.06M
Net Income	-2.05B	-1.79B	-1.83B	223.34M	-1.78B	-527.11M
Balance Sheet
Total Assets	2.99B	2.68B	4.63B	4.91B	4.50B	2.27B
Cash, Cash Equivalents and Short-Term Investments	2.82B	2.55B	4.33B	4.80B	4.25B	2.00B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	162.43M	244.34M	471.07M	408.24M	221.41M	214.95M
Stockholders Equity	2.82B	2.44B	4.16B	4.50B	4.28B	2.06B
Cash Flow
Free Cash Flow	0.00	-1.84B	-1.94B	543.01M	-1.72B	-546.92M
Operating Cash Flow	0.00	-1.84B	-1.94B	543.73M	-1.70B	-544.59M
Investing Cash Flow	0.00	-5.33M	-10.96M	345.00K	-14.70M	-2.36M
Financing Cash Flow	0.00	61.58M	1.48B	0.00	3.98B	1.53B

Chordia Therapeutics Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 108.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:190A, the sentiment is Neutral. The current price of 108 is below the 20-day moving average (MA) of 121.70, below the 50-day MA of 112.32, and below the 200-day MA of 165.44, indicating a neutral trend. The MACD of 4.35 indicates Positive momentum. The RSI at 52.95 is Neutral, neither overbought nor oversold. The STOCH value of 30.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:190A.

Chordia Therapeutics Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4350	70 Outperform	¥15.69B	10.09	―	2.32%	6.60%	27.97%
4890	61 Neutral	¥8.20B	-47.43	―	―	-12.40%	43.42%
2796	60 Neutral	¥6.09B	-41.10	―	2.65%	15.66%	56.93%
8095	58 Neutral	¥19.28B	8.81	―	3.73%	15.00%	-195.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
190A	44 Neutral	¥8.75B	-5.80	―	―	―	―

Chordia Therapeutics Inc. Corporate Events

Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink

Chordia Therapeutics reported non-consolidated results for the quarter ended 30 November 2025 showing no business revenue and a narrowed operating loss of ¥306 million, improving from a ¥624 million loss a year earlier, with quarterly net loss per share reduced to ¥4.24 from ¥9.07. Total assets declined to ¥2.48 billion and equity decreased slightly, but the company maintained a strong equity ratio of 92.1%, continued its no-dividend policy for the current and forecast fiscal year, and projected a full-year net loss of ¥1.96 billion, underscoring its ongoing investment phase and the likelihood of continued losses in the near term for shareholders.

The most recent analyst rating on (JP:190A) stock is a Hold with a Yen105.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.

Chordia Therapeutics to Record Grant Income in Fiscal Year 2026

Chordia Therapeutics Inc. announced the recording of non-operating income from a grant for a research project on therapeutic agents for tumors with RNA splicing mutations. This grant income, amounting to 30 million yen, will be reflected in the company’s financial results for the first quarter of the fiscal year ending August 31, 2026. The financial impact of this grant has already been accounted for in the company’s business forecast, indicating a stable financial outlook.